Conference season and fresh guidance have this blood stock buzzing! 📈 The 9-period EMA just punched above the 21, signaling a bullish shift. RSI is warm but not overheated. That German study and BCA deal are solid catalysts. Volume spiked on the 27th—smart money is listening. This setup says institutions are buying the story. I'm calling it: BUY before the March 2 earnings. #BloodMoney

Cerus is buzzing! Record results, a new purchasing deal, and regulatory wins are serious fuel. 📈 The stock’s pulling back from a recent pop, but it’s holding above key moving averages. RSI is cooling off from overbought levels—healthy for the next leg up. Volume confirms real interest. This looks like a classic "buy the dip" setup on strong news. I’m calling it a BUY. #BloodMoney

Record results, raised guidance, and Germany's new platelet safety recommendation? CERS is cooking! 📈 The stock just surged from $1.48 to $1.62 on huge volume, breaking out of its recent slump. RSI is a healthy 55, not overheated, and it's pushing past key moving averages. This news is the real deal, providing the fuel for a sustained move. This is a BUY. The blood is pumping. #Bullish

German regulators are finally catching up to Cerus's blood safety tech! 📈 That's the real story here. The stock's been grinding higher with RSI in a healthy uptrend – not overheated, just steady buying pressure. This feels like the market is slowly pricing in this regulatory tailwind. All signs point to a BUY before the big breakout. #BloodMoney